These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 19146203)
1. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Costantino D; Guaraldi C Eur Rev Med Pharmacol Sci; 2008; 12(6):411-6. PubMed ID: 19146203 [TBL] [Abstract][Full Text] [Related]
2. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Morali G; Polatti F; Metelitsa EN; Mascarucci P; Magnani P; Marrè GB Arzneimittelforschung; 2006; 56(3):230-8. PubMed ID: 16618016 [TBL] [Abstract][Full Text] [Related]
3. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Le Donne M; Caruso C; Mancuso A; Costa G; Iemmo R; Pizzimenti G; Cavallari V Arch Gynecol Obstet; 2011 Jun; 283(6):1319-23. PubMed ID: 20577750 [TBL] [Abstract][Full Text] [Related]
4. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets. Panay N; Maamari R Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176 [TBL] [Abstract][Full Text] [Related]
5. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. North American Menopause Society Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512 [TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Simon JA; Reape KZ; Wininger S; Hait H Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998 [TBL] [Abstract][Full Text] [Related]
7. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort. Grimaldi EF; Restaino S; Inglese S; Foltran L; Sorz A; Di Lorenzo G; Guaschino S Minerva Ginecol; 2012 Aug; 64(4):321-9. PubMed ID: 22728576 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL Menopause; 2009; 16(5):978-83. PubMed ID: 19390463 [TBL] [Abstract][Full Text] [Related]
9. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Al-Baghdadi O; Ewies AA Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Archer DF Menopause; 2010; 17(1):194-203. PubMed ID: 19602990 [TBL] [Abstract][Full Text] [Related]
12. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ Menopause; 2009; 16(1):132-40. PubMed ID: 18971794 [TBL] [Abstract][Full Text] [Related]
13. Investigating the effect of vitamin D vaginal suppository on sexual function among postmenopausal women: study protocol for a randomized controlled trial. Sarebani Z; Alimoradi Z; Aali E; Mirzadeh M; Chegini V; Abbaspour M; Griffiths MD BMC Womens Health; 2020 Feb; 20(1):27. PubMed ID: 32070323 [TBL] [Abstract][Full Text] [Related]
14. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Stute P Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484 [TBL] [Abstract][Full Text] [Related]
15. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. Manonai J; Songchitsomboon S; Chanda K; Hong JH; Komindr S Maturitas; 2006 May; 54(2):135-40. PubMed ID: 16297576 [TBL] [Abstract][Full Text] [Related]
16. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. Crandall C J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086 [TBL] [Abstract][Full Text] [Related]
18. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Levine KB; Williams RE; Hartmann KE Menopause; 2008; 15(4 Pt 1):661-6. PubMed ID: 18698279 [TBL] [Abstract][Full Text] [Related]
19. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208 [TBL] [Abstract][Full Text] [Related]
20. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Portman D; Palacios S; Nappi RE; Mueck AO Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]